1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Acknowledgments
  7. Disclosure Statement
  8. References
  9. Supporting Information

Gangliosides have been considered as potential targets for immunotherapy because they are overexpressed on the surface of melanoma cells. However, immunization with purified gangliosides results in a very poor immune response, usually mediated by IgM antibodies. To overcome this limitation, we immunized mice with R24, a monoclonal antibody (mAb) that recognizes the most tumor-restricted ganglioside (GD3); our goal was to obtain anti-idiotype (Id) antibodies bearing the internal image of GD3. Animals produced anti-Id and anti-anti-Id antibodies. Both anti-Id and anti-anti-Id antibodies were able to inhibit mAb R24 binding to GD3. In addition, the anti-anti-Id antibodies were shown to recognize GD3 directly. Anti-Id and anti-anti-Id mAb were then selected from two fusion experiments for evaluation. The most interesting finding emerged from the characterization of the anti-anti-Id mAb 5.G8. It was shown to recognize two different GD3-expressing human melanoma cell lines in vitro and to mediate tumor cell cytotoxicity by complement activation and antibody-dependent cellular cytotoxicity. The biological activity of the anti-anti-Id mAb was also tested in a mouse tumor model, in which it was shown to be a powerful growth inhibitor of melanoma cells. Thus, activity of the anti-anti-Id mAb 5.G8 matched that of the prototypic anti-GD3 mAb R24 both in vitro and in vivo. Altogether, our results indicate that the idiotype approach might produce high affinity, specific and very efficient antitumor immune responses. (Cancer Sci 2011; 102: 64–70)

Melanomas and other tumors of neuroectodermal origin have a distinct profile of cell-surface ganglioside expression.(1) The relevance of these carbohydrate antigens as immune targets in cancer cells can be inferred from earlier studies that described the ability of monoclonal antibodies (mAb) raised against gangliosides to induce complement-dependent cytotoxicity (CDC) in melanoma, neuroblastoma, sarcoma and astrocytoma cell lines.(2) Generally, immunization with whole tumor cells or cell lysates induces low titer IgM antibodies to carbohydrate antigens, but the use of conjugated vaccines can produce high titers of IgM and IgG antibodies.(3) The best vaccine design involves the conjugation of the antigen to keyhole limpet hemocyanin (KLH) and the use of saponins QS-21 and GPI-0100 as adjuvants.(4)

In contrast to normal cells, transformed melanocytes abundantly express disialoganglioside 3 (GD3). R24 is a mouse mAb that specifically recognizes GD3 and mediates in vitro effector functions such as CDC and antibody-dependent cellular cytotoxicity (ADCC).(5) It also stimulates proliferation of GD3-expressing T cells derived from human peripheral blood(6) and was shown to enhance lymphocyte RNA expression of IL-4, IL-10 and IFN-γ.(7) Normal melanocytes are not lysed by the R24-directed immune response due to their low GD3 expression. In contrast to the potent in vitro activity of R24, its effect in nu/nu mice bearing human melanoma grafts is much more modest; tumor inhibition was observed only when R24 treatment started within 3 days of tumor cell inoculation and no effect was shown on established tumors.(8) As a single agent, R24 was shown to induce clinical responses in patients with metastatic melanoma, including complete remissions.(9,10) Nevertheless, the dose-dependent toxicity of R24 can be substantial and constitutes a serious limitation for its clinical use.(11–14)

Anti-idiotype (anti-Id) antibodies that mimic a defined antigenic epitope are a relatively unexplored albeit potentially useful therapeutic tool. We hypothesized that an anti-Id antibody, being a protein, should be more immunogenic than GD3, a thymus-independent antigen. In support of this assumption, promising results have been reported with anti-Id antibodies in the context of several experimental models based on pathogen-derived(15–17) and tumor-associated(18–27)antigens. We have also previously described an anti-Id monoclonal antibody that was able to mimic glycoprotein carcinoembryonic antigen (CEA) and elicit an anti-anti-Id mAb that recognized the antigen in vitro and in vivo.(28–30) In the present study, we immunized BALB/c mice with the mAb R24 with the expectation of obtaining anti-Id antibodies bearing the internal image of GD3. Animals were shown to produce anti-Id and anti-anti-Id antibodies of IgM and IgG classes. One anti-Id antibody clone was selected for detailed evaluation. However, the most interesting finding emerged from the characterization of the anti-anti-Id antibody. The well-defined prototypic anti-GD3 monoclonal antibody R24 was used as a control in the assays of binding, cytotoxic activity in vitro and for the ability to protect against tumor challenge. We found that this anti-anti-Id mAb is a powerful growth inhibitor of melanoma cells in vitro and in vivo.

Materials and Methods

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Acknowledgments
  7. Disclosure Statement
  8. References
  9. Supporting Information

Animals.  Eight-week-old female BALB/c and C57BL/6 mice were obtained from the National Institute of Pharmacology of the Federal University of São Paulo (UNIFESP) and from the São Paulo University animal facilities. All animal experiments were carried out in compliance with the NIH-Guidelines for the care and use of laboratory animals, and approved by the Animal Ethics Committee of UNIFESP.

Cell lines.  Culture conditions followed standard protocols. Additional information is available in the Supporting Information.

Immunization.  BALB/c mice were immunized with 100 μg of purified antibody (R24, 5.E3 or irrelevant mAb), coupled to KLH (Sigma, St Louis, MO, USA), as previously described.(29)

Production of anti-Id and anti-anti-Id mAb.  Two days before cell fusion, mice received a final booster of 100 μg of KLH-coupled mAb R24 administered intravenously. Hybridoma cells were produced as previously described.(31,32) Double screening, made by both competitive inhibition and indirect enzyme immunoassays (EIA), allowed the detection of anti-Id and anti-anti-Id colonies. After cloning by limiting dilution and expansion of positive clones, large amounts of antibodies were obtained by the production of ascites in BALB/c mice. The mAb were purified by affinity chromatograghy in a Protein G-Sepharose column (Amersham Biosciences, Uppsala, Sweden). Immunoglobulin isotyping was performed with a Mouse Typer Isotyping Panel kit (Bio-Rad Laboratories, Hercules, CA, USA).

In vivo protection experiment.  Immune deficient C57BL/6 mice were generated by a single 6-Gy dose of whole body γ-irradiation from a 137Cs source as previously described;(23–35) animals were maintained in a semi-sterile environment and fed with autoclaved meal and water containing 2 mg/mL gentamycin. 1 × 106 SKMel-28 cells in 0.1 mL sterile PBS were inoculated subcutaneously in two sites at the femur base of irradiated 8-week-old C57BL/6 mice on day 1. Four groups of five animals received an intraperitoneal injection of 50 μg of either one of the mAb (5.G8, R24 or the irrelevant 5.D11) or 100 μL of PBS. Injections were administered daily for 7 days from day 1. The animals were evaluated daily for tumor size by measuring the two largest diameters as described elsewhere.(36)

Statistical analysis.  Statistical analysis was performed using the GraphPad Prism V.3 statistical software (La Jolla, CA, USA). Data were analyzed by t-tests when two groups were compared and by one-way analysis of variance (anova), followed by Dunnett’s post-test, in the cases of multiple comparisons. A P value <0.05 was considered significant. Means ± SD are shown.

The EIA, CDC, ADCC and antibody binding assays were performed according to standard protocols. A detailed description is presented in the Supporting Information.


  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Acknowledgments
  7. Disclosure Statement
  8. References
  9. Supporting Information

Evaluation of the antibody response to mAb R24 immunization.  Serum samples from BALB/c mice immunized with the mAb R24 conjugated to KLH were analyzed by competitive inhibition EIA. Figure 1A shows that the pool of sera from mice that have been immunized twice was able to inhibit 42.20 ± 10.78% of the binding of the mAb R24 to GD3 adsorbed to a solid phase. In addition, it was possible to detect the presence of anti-anti-Id antibodies in the sera by indirect EIA. Figure 1B shows the titration of GD3-binding anti-anti-Id antibodies in the sera of mice that have been immunized three times with the mAb R24.


Figure 1.  Detection of anti-idiotype (Id) and anti-anti-Id antibodies. Five mice were injected subcutaneously with mAb R24-keyhole limpet hemocyanin and bled after each immunization to provide pooled sera for enzyme immunoassays. (A) Inhibition of mAb R24 binding to GD3, indicating the presence of inhibitory anti-Id antibodies in the serum samples diluted 1:200. (B) Titration of GD3-binding anti-anti-Id antibodies in the sera after three immunizations. All assays were performed in triplicate. Results were analyzed by the t test.

Download figure to PowerPoint

Isolation of monoclonal antibodies.  Given the high titers of anti-Id and anti-anti-Id antibodies present in the serum of mAb R24-immunized mice, we decided to use the spleens of these animals as the source of clonal cell populations for the production of both types of antibodies. Two fusion experiments raised eight anti-Id and five anti-anti-Id mAb. Isotyping of the anti-Id antibodies revealed one IgM, one IgG1 and six IgG2a isotypes. Anti-anti-Id antibodies were also checked and two IgM, two IgG1 and one IgG3 isotypes were identified. All of the obtained mAb had kappa light chains (Table 1). Two of these antibodies, 5.E3 and 5.G8, were characterized in detail.

Table 1.   Antibody isotyping
mAbAnti-IdAnti-anti-IdIg isotype
  1. All antibodies had kappa light chains. Bold refers to the antibodies selected for further analysis. Id, idiotype.

1.F3 XIgM
2.G11 XIgG3
2.C6X IgG2a
3.B7X IgG2a
3.A5 XIgG1
4.B2X IgM
4.C3X IgG1
4.E8X IgG2a
5.G8 XIgG1
5.C3 XIgM
5.C12X IgG2a
5.H9X IgG2a
5.E3X IgG2a

Figure 2A shows the inhibition curve of the binding of the mAb R24 to GD3 using increasing amounts of the anti-Id mAb 5.E3. A 50% binding inhibition was achieved with a 10 μg/mL concentration. This inhibition curve is similar to that obtained with other high-affinity anti-Id antibodies described in the literature.(30,37,38)


Figure 2.  Characterization of anti-idiotype (Id) and anti-anti-Id mAb. (A) The anti-Id mAb 5.E3 inhibited the binding of the mAb R24 to GD3 in a dose-dependent manner over a 0–100 μg/mL concentration range. No specific inhibition was observed when an irrelevant mAb was used as a control. (B) The polar lipid fraction extracted from SKMel-28 cells was used to coat the enzyme immunoassay plates. The anti-anti-Id mAb 5.G8 recognized the crude extract similar to the mAb R24. Statistical analysis was performed by one-way anova with Dunnett’s post-test. (C) The reactivity of biotinylated mAb 5.E3 was tested against mAb 5.G8, mAb R24 or an irrelevant mAb. All experiments were performed in quadruplicate.

Download figure to PowerPoint

Next, we examined the reactivity of the anti-anti-Id mAb 5.G8 against crude extracts of the GD3-positive SKMel-28 cells. Figure 2B shows the binding activity to the polar lipid fraction by indirect EIA. The mAb 5.G8 and the positive control antibody R24 efficiently recognized the fraction containing glycosphingolipids that includes gangliosides, as opposed to the irrelevant antibody control (P < 0.001). Altogether, our data allowed us to envisage a model in which the mAb R24, 5.E3 and 5.G8 belong to an interactive idiotype-anti-idiotype network. In order to test this model, we biotinylated the anti-Id mAb 5.E3 and measured its binding ability to the mAb R24 and to the anti-anti-Id mAb 5.G8. The anti-Id antibody recognized equally well the mAb R24 and the mAb 5.G8 as illustrated in Figure 2C.

Anti-GD3 antibodies generated by anti-Id mAb 5.E3 immunization.  Groups of five mice were immunized with the anti-Id mAb 5.E3 or an IgG2a isotype control mAb, both conjugated to KLH. Figure 3 shows the presence of GD3-binding anti-anti-Id antibodies in the sera of mice immunized twice with the mAb 5.E3. The reactivity of the sera derived from 5.E3-immunized animals was significantly higher than that observed with samples derived from isotype-vaccinated control mice (P < 0.0001). In addition, no GD3-binding antibody was detected in the pre-immune sera.


Figure 3.  Immunization with the anti-idiotype (Id) mAb 5.E3 induces GD3-binding anti-anti-Id antibodies. Sera at 1/200 dilution from mice that were immunized with the mAb 5.E3 or an irrelevant IgG2a mAb, both coupled to keyhole limpet hemocyanin, were tested by indirect EIA for the presence of GD3-binding antibodies. Pre-immune sera were also used as a control. Statistical analysis was performed by the t test.

Download figure to PowerPoint

The anti-anti-Id antibody recognizes intact human melanoma cells.  In order to verify whether the anti-anti-Id mAb 5.G8 could recognize the GD3 antigen in its native status in the context of intact cells, we tested its reactivity against intact SKMel-28 melanoma cells. Figure 4 shows that the mAb 5.G8 and the control mAb R24 were capable of recognizing 87.73 ± 2.75% and 100% of the cells, respectively. Similar data were obtained with another human melanoma cell line, MeWo, that was 65.55 ± 1.42% positive for binding to the mAb 5.G8 and 72.68 ± 1.72% positive for binding to the mAb R24 (Fig. 4). In contrast, both antibodies have shown a much lower reactivity to the human keratinocyte cell line Hacat: 16.78 ± 0.47% for the mAb 5.G8 and 18.96 ± 0.36% for the mAb R24. They have also reacted very poorly against another epithelial tumor, the human colon adenocarcinoma CO112 (3.78 ± 0.29% for the mAb 5.G8 and 1.87 ± 0.45% for the mAb R24), and against the murine embryonic fibroblast cell line NIH3T3 (7.21 ± 3.35% for the mAb 5.G8 and 9.43 ± 2.40% for the mAb R24).


Figure 4.  Binding of the anti-anti-idiotype (Id) mAb 5.G8 to different cell lines. The GD3-expressing human melanoma cell lines (SKMel-28 and MeWo) as well as the cell lines Hacat, NIH3T3 and CO112 were grown in 96-well plates and fixed as described in the Supporting Information. Primary antibodies were added and a peroxidase-conjugated goat anti-mouse IgG was used to detect antibody binding. MAb R24 was used as a positive control and an irrelevant murine IgG1 antibody was used as an isotype control. The assay was performed eight times.

Download figure to PowerPoint

Cytotoxic activity of the anti-anti Id mAb 5.G8 in vitro.  The mAb 5.G8 was able to promote antibody-mediated complement-dependent lysis of SKMel-28 cells (Fig. 5A); these cells were also targets for antibody-dependent cellular cytotoxicity (Fig. 5B). The specific lysis achieved in the complement fixation assay was 65.47 ± 13.23% for the mAb 5.G8 and 97.95 ± 0.82% for the mAb R24; the specific lysis values in the ADCC test were 61.41 ± 1.57% and 71.00 ± 4.49%, respectively. The cytotoxicity levels induced by these antibodies in both tests were substantially higher than the background levels produced by the isotype control (P < 0.001). In contrast to the mAb 5.G8, the mAb R24 could lyse target cells in the absence of complement or effector cells.


Figure 5. In vitro biological activities. (A) Complement-mediated cytotoxicity and (B) antibody-dependent cellular cytotoxicity (ADCC) assays were performed with purified mAb (50 μg/mL). The cell line SKMel-28 was used as the target in both tests. Fresh rabbit serum was used as the source of complement (diluted 1/8). Complement-dependent cytotoxicity was calculated by cell viability analysis at the end of the experiment. For the ADCC assay, peritoneal exudate was used as the source of effector cells and 51Cr release was quantified after 48 h incubation. The Effector : Target ratio was 200:1. Both assays were performed in quadruplicate. Statistical analysis was performed using one-way anova with Dunnett’s post-test.

Download figure to PowerPoint

In vivo antitumor activity of the anti-anti-Id mAb 5.G8.  C57BL/6 mice were rendered immune deficient by irradiation preconditioning and were subsequently inoculated with GD3-expressing human melanoma SKMel-28 cells. The animals were divided into four groups that received one of the following treatments: (i) the mAb 5.G8; (ii) the mAb R24; (iii) an irrelevant mAb; or (iv) PBS, as described in the “Materials and Methods”. All mice (5/5) in the two negative control groups developed tumors by day 28 compared with 4/5 and 1/5 of the animals injected with the mAb 5.G8 or the mAb R24, respectively. Although there was no major difference between the mAb 5.G8 group and the negative control groups with regards to the number of tumor-free animals, there were substantial differences in tumor size and growth profile (Fig. 6). Tumor growth was observed in the two negative control groups as early as day 17 as opposed to the mice injected with the 5.G8 and anti-GD3 control antibodies in which the tumors took longer to be measurable. Figure 6 shows the tumor growth curve between days 20 and 28 from one representative experiment out of three. The lesions were barely visible on day 22 in the groups injected with the mAb 5.G8 or the mAb R24 and the average volume was smaller than 1 mm3 on day 28 (0.071 ± 0.073 cm3 for 5.G8 and 0.04 ± 0.1 cm3 for R24). Nevertheless, tumor progression was much more evident in the negative control groups, on day 28 reaching an average volume of 0.480 ± 0.249 cm3 in the animals that received the irrelevant antibody and 0.513 ± 0.284 cm3 in those that were injected with PBS. The evaluation on day 28 of tumor growth by anova followed by Dunnett’s post-test revealed a significant difference between the PBS control group and the mAb 5.G8 group (P < 0.001) and between the PBS and the mAb R24 groups (P < 0.001). Similar differences were found when the irrelevant antibody group was compared with the mAb 5.G8 group (P < 0.05) and with the mAb R24 group (P < 0.05). In conclusion, the anti-melanoma effect in vivo demonstrated with the anti-anti-Id mAb 5.G8 was virtually identical to that observed with the mAb R24 (Fig. 6).


Figure 6.  Ability of mAb to inhibit tumor growth in vivo. Four groups of five C57BL/6 mice were irradiated and grafted with SKMel-28 cells on day 1. During the first 7 days of the experiment, mice received one of the following treatments: (i) PBS; (ii) irrelevant antibody; (iii) mAb R24; or (iv) anti-anti-idiotype (Id) mAb 5.G8, as described in the “Materials and Methods”. Animals were checked daily for tumor growth. The average tumor volume recorded during the fourth week of the experiment was plotted. These results are representative of three experiments.

Download figure to PowerPoint


  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Acknowledgments
  7. Disclosure Statement
  8. References
  9. Supporting Information

Immunological tolerance is a major issue in cancer immunotherapy. To break the inability of the host’s immune system to recognize and react properly against malignant cells is particularly challenging given that tumor-associated antigens are self, poorly immunogenic molecules. Normal melanocytes express the mono-sialo GM3 as their major ganglioside, whereas the growth and metastatic potential of malignant melanoma correlate with excessive synthesis of GD3.(39) Although little is known about the precise composition of many gangliosides that are expressed in tumors, shedding of GD3 into the circulation has been observed in patients bearing certain malignancies.(39) It has been shown by several groups that this ganglioside might promote tumor growth and cell–cell adhesion.(40,41) Although GD3 is present in melanoma cells, its expression in normal tissues is limited and not related to altered cellular behavior. Altogether, these reports support the idea that GD3 might be a good target for the antitumor immune response and suggest the potential usefulness of an anti-GD3 antibody-based strategy in cancer therapy.(9,14,42,43) However, as the main antigenic epitopes in GD3 are carbohydrates, only a very weak and T-cell-independent immune response can be stimulated when it is used as an immunogen. Several attempts have been made to address the therapeutic potential of the anti-GD3-specific immune response.(14,42–50) Nevertheless, the anti-GD3 immune response was shown to be short-lived and mainly constituted by IgM antibodies.(1)

The anti-idiotypic antibody approach represents an alternative to circumvent the poor immunogenicity of GD3 and the toxicity of the mAb R24(11–14) in cancer therapy. The remarkable ability of anti-Id antibodies to mimic the original antigen has been shown in several models.(15–28) Anti-Id antibodies might induce a specific immune response against tumor-associated antigens, such as the carcinoembryonic antigen(29,51) and the human high molecular weight melanoma-associated antigen(52) among others.(22–27) In addition, two anti-idiotype R24 antibodies (BEC2 and BEC3) have been previously isolated.(53) Although BEC3 was incapable of eliciting anti-GD3 responses, BEC2 was shown to induce IgM but no IgG anti-GD3 antibodies in a fraction (22%) of immunized melanoma patients.(54–56) The application of these antigen surrogates in cancer immunotherapy is particularly appealing when the antigen is not a protein, as in the case of gangliosides. However, the fine specificity profile of anti-GD3 antibodies and of their anti-idiotypic counterparts might vary considerably with significant differences in binding, affinity and immunogenicity.(44–50,53) Thus, the search for novel anti-Id and anti-anti-Id antibodies, such as the ones described in this paper, might lead to the identification of molecules with the ability to induce high affinity IgG responses with increased antitumor activity in a larger fraction of immunized individuals.

In the present report, we have used the mAb R24 coupled to KLH to immunize BALB/c mice. An anti-Id immune response was identified after the first immunization as the serum inhibited binding of the mAb R24 to GD3. Anti-anti-Id antibodies capable of binding GD3 could also be detected in the third immunization. In view of these results, both anti-Id and anti-anti-Id mAb were produced in mice in order to evaluate the efficiency of the GD3-associated idiotypic network. We found that the anti-Id and anti-anti-Id antibody secreting clones belonged to different Ig classes and subclasses. The observed Ig isotype diversity suggests an effective T cell cooperation in the development of the anti-Id and anti-anti-Id immune responses; it is also likely to contribute to a higher efficiency of the immune response because it might augment the cytotoxic effect triggered and/or mediated by antibodies.

The monoclonal anti-Id antibody selected for detailed analysis in the present study, clone 5.E3, was able to inhibit the binding of the mAb R24 to GD3 in a dose-dependent fashion. When used as an immunogen, the mAb 5.E3 also elicited a GD3-binding anti-anti-Id humoral immune response in mice. The participation of the mAb 5.E3 in a cascade of idiotype–anti-idiotype interactions is supported by its ability to bind the mAb R24 as well as the anti-anti-Id mAb 5.G8.

The mAb 5.G8 and the mAb R24 were capable of recognizing the GD3 ganglioside in the polar lipid fraction of SKMel-28 cell extracts. Reactivity of the anti-anti-Id antibody was also tested in intact cells; five cell lines, including two human GD3-expressing melanoma cell lines, were tested for antibody binding. The mAb 5.G8 was shown to recognize both melanoma cell lines at comparable levels to those obtained with the original anti-GD3 mAb R24. It is noteworthy that both antibodies recognized SKMel-28 cells somewhat better than MeWo cells (25% higher reactivity); this finding is in agreement with the reported higher expression of GD3 in SKMel-28 cells.(8)

Antibody-dependent cellular cytotoxicity and CDC are important immune effector mechanisms and the ability to promote target lysis might be a valuable asset of antibodies considered for therapeutic use. Our analysis of the mAb 5.G8 revealed that it was highly effective in mediating lysis of target cells either by ADCC or by fixing complement. The ADCC activity was observed when activated peritoneal macrophages were used as effector cells, but not when splenocytes were the source of the effector cells (data not shown). At first sight, the mAb 5.G8 seemed to be less efficient than the mAb R24 in ADCC and CDC. However, the mAb R24 exhibits direct cytotoxic activity as evidenced by the aggregation of melanoma cells in culture, which usually leads to detachment and subsequent death.(8) In addition, the mAb R24 is an IgG3 that might form noncovalent molecular aggregates at a high concentration, thereby increasing the lysis of target cells in vitro.(57–60) If one accounts for this direct cytotoxicity, the mAb R24 and the mAb 5.G8 have fairly similar activities in ADCC and CDC. Indeed, our results indicate that the mAb 5.G8 was even slightly more efficient than the mAb R24 in its ability to fix complement (59.83 ± 12.29% for the mAb 5.G8 and 52.66 ± 0.82% for the mAb R24), as well as to promote ADCC (58.34 ± 1.57% and 49.20 ± 2.78%, respectively) if one discounts in each case the lysis obtained by the antibody alone.

In our in vivo tumor model, animals were preconditioned by sublethal irradiation and inoculated with the human melanoma cell line SKMel-28. All animals in the negative control groups developed tumors that were approximately 0.5 cm3 on day 28. This was in sharp contrast with groups that were treated with the anti-anti-Id or GD3-specific antibodies in which there were tumor-free animals at the end of the observation period and the average volume of the lesions when present was under 1 mm3. Thus, our data indicate that passive transfer of the anti-anti-Id mAb 5.G8 confers protection in the experimental model described here by delaying tumor growth.

We present evidence that immunization with the anti-GD3 mAb R24 induces a cascade of idiotype–anti-idiotype interactions. While anti-Id interactions are likely to occur in the context of natural immune responses, a definitive picture of their immune-regulatory importance remains to be established. However, our results demonstrate that the anti-Id approach works even in a T-cell-independent system and suggests a potential role to play in cancer immunotherapy. The isotype diversity also constitutes an advantage of the anti-Id strategy; this is particularly relevant if we consider that such diversity occurred in a system where the original antigen is a glycolipid that is unlikely to stimulate an efficient immune response on its own. To our knowledge, this is the first report on a melanoma-specific anti-anti-Id mAb that shows direct antitumor activity in vivo in a T-cell-independent way; this anti-anti-Id mAb might represent an alternative for cancer treatment if further studies identify a favorable profile in terms of toxicity, inflammatory reaction and tumor killing.


  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Acknowledgments
  7. Disclosure Statement
  8. References
  9. Supporting Information

This work was supported by Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP). A.S.R. and C.B.P. were recipients of scholarships from FAPESP and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), respectively. The authors are indebted to Dr Roger Chammas for his critical comments and suggestions, Ivan Hariton Cordeiro for technical assistance and Mauro Cardoso Pereira for animal care support.


  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Acknowledgments
  7. Disclosure Statement
  8. References
  9. Supporting Information
  • 1
    Livingston PO. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines. Immunol Rev 1995; 145: 14766.
  • 2
    Zhang S, Helling F, Lloyd KO, Livingston PO. Increased tumor cell reactivity and complement-dependent cytotoxicity with mixtures of monoclonal antibodies against different gangliosides. Cancer Immunol Immunother 1995; 40: 8894.
  • 3
    Ragupathi G. Carbohydrate antigens as targets for active specific immunotherapy. Cancer Immunol Immunother 1996; 43: 1527.
  • 4
    Ragupathi G, Gathuru J, Livingston PO. Antibody inducing polyvalent cancer vaccines. Cancer Treat Res 2005; 123: 15780.
  • 5
    Pukel CS, Lloyd KO, Travassos LR, Dippold WG, Oettgen HF, Old LJ. GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody. J Exp Med 1982; 155: 113347.
  • 6
    Norihisa Y, McVicar DW, Ghosh P et al. Increased proliferation, cytotoxicity, and gene expression after stimulation of human peripheral blood T lymphocytes through a surface gangliosides (GD3). J Immunol 1994; 152: 48595.
  • 7
    Triozzi PL, Shah JJ, Wang WQ et al. Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent cellular cytotoxicity. Cancer Biother Radiopharm 2006; 21: 55360.
  • 8
    Welt S, Carswell E, Vogel C-W, Oettgen HF, Old LJ. Immune and nonimmune effector functions of IgG3 mouse monoclonal antibody R24 detecting the disialogangliosides GD3 on the surface of melanoma cells. Clin Immunol Immunopathol 1987; 45: 21429.
  • 9
    Houghton AN, Mintzer D, Cordon-Cardo C. Mouse monoclonal IgG3 antibody detecting GD3 ganglioside. A phase I trial in patients with malignant melanoma. Proc Natl Acad Sci U S A 1985; 82: 12426.
  • 10
    Nasi ML, Meyers M, Livingston PO, Houghton AN, Chapman PB. Anti-melanoma effects of R24, a monoclonal antibody against GD3 ganglioside. Melanoma Res 1997; 7 (Suppl 2): S15562.
  • 11
    Iglesias-Bartolomé R, Crespo PM, Gomez GA, Daniotti JL. The antibody to GD3 ganglioside, R24, is rapidly endocytosed and recycled to the plasma membrane via the endocytic recycling compartment. FEBS J 2006; 273: 174458.
  • 12
    Dippold W, Bernhard H, Meyer zum Buschenfelde KH. Immunological response to intratecal and systemic treatment with ganglioside antibody R24 in patients with malignant melanoma. Eur J Caner 1994; 30A: 13744.
  • 13
    Kirkwood JM, Mascari RA, Edington HD et al. Analysis of therapeutic and immunological effects of R24 anti-GD3 monoclonal antibody in 37 patients with metastatic melanoma. Cancer 2000; 88: 2693702.
  • 14
    Scott AM, Lee F-T, Hopkins W et al. Specific targeting, biodistribution, and lack of immunogenicity of chimeric anti-GD3 monoclonal antibody KM871 in patients with metastatic melanoma: results of a phase I trial. J Clin Oncol, 2001; 19: 397687.
  • 15
    Souza AR, Gesztesi J-L, Moraes JZ, Cruz CRB, Mariano M, Lopes JD. Evidence of idiotypic modulation in the immune response to gp43, the major antigenic component of Paracoccidioides bransiliensis in both mice and humans. Clin Exp Immunol 1998; 114: 408.
  • 16
    Shearer MH, Dalgleish AG, Chanh TC, Kennedy RC. Idiotype cascades associated with the CD4-HIV glycoprotein 120 interaction: immunization with anti-idiotypic antibodies induces anti-anti-idiotypic responses with anti-CD4 specificity and in vitro neutralizing activity. AIDS Res Hum Retroviruses 2000; 16: 7786.
  • 17
    Vani J, Nayak R, Shaila MS. Immunization of mice with DNA coding for the variable regions of anti-idiotypic antibody generates antigen-specific response. Vaccine 2007; 25: 492230.
  • 18
    Chang CC, Hernandez-Guzman FG, Luo W, Wang X, Ferrone S, Ghosh D. Structural basis of antigen mimicry in a clinically relevant melanoma antigen system. J Biol Chem 2005; 280: 4154652.
  • 19
    Neninger E, Díaz RM, de la Torre A et al. Active immunotherapy with 1E10 anti-idiotype vaccine in patients with small cell lung cancer: report of a phase I trial. Cancer Biol Ther 2007; 6: 14550.
  • 20
    Hernández AM, Toledo D, Martínez D et al. Characterization of the antibody response against NeuGcGM3 ganglioside elicited in non-small cell lung cancer patients immunized with an anti-idiotype antibody. J Immunol 2008; 181: 662534.
  • 21
    Pal S, Saha A, Mohanty K et al. Generation of Her-2/neu vaccine utilizing idiotypic network cascade. Cancer Biol Ther 2007; 6: 191625.
  • 22
    Sabbatini P, Dupont J, Aghajanian C et al. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer. Clin Cancer Res 2006; 12: 550310.
  • 23
    Mohanty K, Saha A, Pal S et al. Anti-tumor immunity by an anti-idiotype antibody mimicking human Her-2/neu. Breast Cancer Res Treat 2007; 104: 111.
  • 24
    Reinartz S, Kohler S, Schlebusch H et al. Vaccination of patients with advanced ovarian carcinoma with anti-idiotype ACA125: immunological response and survival (phase Ib/II). Clin Cancer Res 2004; 10: 15807.
  • 25
    Lee G, Ge B. Inhibition of in vitro tumor cell growth by RP215 monoclonal antibody and antibodies raised against its anti-idiotype antibodies. Cancer Immunol Immunother 2010; 59: 134756.
  • 26
    Pfisterer J, du Bois A, Sehouli J et al. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. Ann Oncol 2006; 17: 156877.
  • 27
    Basak S, Birebent B, Purev E et al. Induction of cellular immunity by anti-idiotypic antibodies mimicking GD2 ganglioside. Cancer Immunol Immunother 2003; 52: 14554.
  • 28
    Pignatari GC, Takeshita D, Parise CB, Soares FA, de Moraes JZ, Han SW. Carcinoembryonic antigen (CEA) mimicry by an anti-idiotypic scFv isolated from anti-Id 6.C4 hybridoma. J Biotechnol 2007; 127: 61525.
  • 29
    Moraes JZ, Carneiro CRW, Buchegger F, Mach J-P, Lopes JD. Induction of an immune response through the idiotypic network with monoclonal anti-idiotype antibodies in the carcinoembrionic antigen system. J Cell Biochem 1992; 50: 32435.
  • 30
    Moraes JZ, Geztesi J-L, Wastermann P, leDussal J-M, Lopes JD, Mach J-P. Anti-idiotypic monoclonal antibody AB3, reacting with the primary antigen (CEA), can localize human colon-carcinoma xenografts as efficiently as AB1. Int J Cancer 1994; 57: 58691.
  • 31
    Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 4957.
  • 32
    St.Groth S, Scheidegger D. Production of monoclonal antibodies: strategies and tactics. J Immunol Methods 1980; 35: 100111.
  • 33
    Coligan JE, Kruisbbek AM, Margulies DH, Shevach EM, Strober W. Current Protocols in Immunology. New York: John Wiley & Sons, Inc., 1994.
  • 34
    Gorelik E, Xu F, Henion T, Anaraki F, Galili U. Reduction of metastatic properties of BL6 melanoma cells expressing terminal fucose(alfa)1-2-galactose after alfa1,2-fucosyltranferase cDNA transfection. Cancer Res 1997; 57: 3326.
  • 35
    Jackson RJ, Engelman RW, Coppola D, Cantor AB, Wharton W, Pledger WJ. p21cip1 nullizygosity increases tumor metastasis in irradiated mice. Cancer Res 2003; 63: 30215.
  • 36
    Spicer AP, Rowse GJ, Linder TK, Gendler SJ. Delayed mammary tumor progression in Muc-1 null mice. J Biol Chem 1995; 270: 30093101.
  • 37
    Burlingham WJ, Jankowska-Gan E, DeVito-Haynes L et al. HLA (A*0201) mimicry by anti-idiotypic monoclonal antibodies. J Immunol 1998; 161: 670514.
  • 38
    Torres M, May R, Scharff MD, Casadevall A. Variable-region-identical antibodies differing in isotype demonstrate differences in fine specificity and idiotype. J Immunol 2005; 174: 213242.
  • 39
    Portoukalian J, David MJ, Shen X, Richard M, Dubreuil C. Tumor size-dependent elevations of serum gangliosides in patients with head and neck carcinomas. Biochem Int 1989; 18: 75965.
  • 40
    Hakomori S. Glycosphingolipids in cellular interaction, differentiation, and oncogenesis. Annu Rev Biochem 1981; 50: 73364.
  • 41
    Hakomori S. Structure and function of glycosphingolipids in transmembrane signalling and cell–cell interactions. Biochem Soc Trans 1993; 21: 58395.
  • 42
    Soiffer RJ, Chapman PB, Murray C et al. Administration of R24 monoclonal antibody and low-dose interleukin-2 for malignant melanoma. Clin Cancer Res 1997; 3: 1724.
  • 43
    Choi BS, Sondel PM, Hank JA et al. Phase I trial of combined treatment with ch14.18 and R24 monoclonal antibodies and interleukin-2 for patients with melanoma or sarcoma. Cancer Immunol Immunother 2006; 55: 76174.
  • 44
    Ando S, Yu RK, Scarsdale JN, Kusunoki S, Prestegard JH. High resolution proton NMR studies of gangliosides. Structure of two types of GD3 lactones and their reactivity with monoclonal antibody R24. J Biol Chem 1989; 264: 347883.
  • 45
    Chapman PB, Gillies SD, Houghton AN, Reilly RM. Mapping effector functions of a monoclonal antibody to GD3 by characterization of a mouse-human chimeric antibody. Cancer Immunol Immunother 1994; 39: 198204.
  • 46
    Giaccone G, Debruyne C, Felip E et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer. J Clin Oncol 2005; 23: 685464.
  • 47
    Bottomley A, Debruyne C, Felip E et al. Symptom and quality of life results of an international randomised phase III study of adjuvant vaccination with Bec2/BCG in responding patients with limited disease small-cell lung cancer. Eur J Cancer 2008; 44: 217884.
  • 48
    Kaminski MJ, MacKenzie CR, Mooibroek MJ et al. The role of homophilic binding in anti-tumor antibody R24 recognition of molecular surfaces. Demonstration of an intermolecular beta-sheet interaction between vh domains. J Biol Chem 1999; 274: 5597604.
  • 49
    Ritter G, Ritter-Boosfeld E, Adluri R et al. Analysis of the antibody response to immunization with purified O-acetyl GD3 gangliosides in patients with malignant melanoma. Int J Cancer 1995; 62: 66872.
  • 50
    Tai T, Kawashima I, Furukawa K, Lloyd KO. Monoclonal antibody R24 distinguishes between different N-acetyl- and N-glycolylneuraminic acid derivatives of ganglioside GD3. Arch Biochem Biophys 1988; 60: 515.
  • 51
    Bhattacharya-Chatterjee M, Mukerjee S, Biddle W, Foon KA, Köhler H. Murine monoclonal antibody as a potential network antigen for human carcinoembryonic antigen. J Immunol 1990; 145: 275865.
  • 52
    Yang H, Chen ZJ, Kageshita T, Yamada M, Ferrone S. Idiotypic cascate in the human high molecular weight melanoma-associated antigen system: fine specificity and idiotypic profile of anti-anti-idiotypic monoclonal antibodies. Eur J Immunol 1993; 23: 16717.
  • 53
    Chapman PB, Houghton AN. Induction of IgG antibodies against GD3 ganglioside in rabbits by an anti-idiotypic monoclonal antibody. J Clin Invest 1991; 88: 18692.
  • 54
    Yao T-J, Meyers M, Livingston PO, Houghton AN, Chapman PB. Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. Clin Cancer Res 1999; 5: 7781.
  • 55
    Chapman PB, Williams L, Salibi N, Hwu W-J, Krown SE, Livingston PO. A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside. Vaccine 2004; 22: 29049.
  • 56
    Chapman PB, Wu D, Ragupathi G et al. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside. Clin Cancer Res 2004; 10: 471723.
  • 57
    Grey HM, Hirst JW, Cohan MJ. A new mouse immunoglobulin: IgG3. J Exp Med 1971; 133: 289304.
  • 58
    Natsume A, In M, Takamura H et al. Engineered antibodies of IgG1/IgG3 mixed isotype with enhanced cytotoxic activities. Cancer Res 2008; 68: 386372.
  • 59
    Duah NO, Weiss HA, Jepson A, Tetteh KK, Whittle HC, Conway DJ. Heritability of antibody isotype and subclass responses to Plasmodium falciparum antigens. PLoS ONE 2009; 4 (10): e7381.
  • 60
    Akiyoshi DE, Sheoran AS, Rich CM, Richard L, Chapman-Bonofiglio S, Tzipori S. Evaluation of Fab and F(ab′)2 fragments and isotype variants of a recombinant human monoclonal antibody against shiga toxin 2. Infect Immun 2010; 78: 137682.

Supporting Information

  1. Top of page
  2. Abstract
  3. Materials and Methods
  4. Results
  5. Discussion
  6. Acknowledgments
  7. Disclosure Statement
  8. References
  9. Supporting Information

Data S1. Materials.

CAS_1771_sm_Supportinginformation.doc41KSupporting info item

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.